Birth outcomes following intrauterine exposure to electronic nicotine delivery systems: a systematic review and meta-analysis.

Nicotine Tob ResSep 24, 2026
Clinical ResearchObstetrics & Gynecology

Samantha Johnstone, Ashley Schenkel, Samantha Canazzi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined birth outcomes associated with intrauterine exposure to electronic nicotine delivery systems (ENDS) compared to non-exposed and other nicotine-exposed neonates. The analysis included 22 studies and found that ENDS exposure was associated with significantly greater odds of preterm birth compared to non-exposed births. Additionally, lower birthweight was observed in ENDS-exposed neonates.

Key findings

  • ENDS exposure was linked to significantly greater odds of preterm birth compared to non-exposed births.
  • No significant difference in small for gestational age (SGA) between ENDS-exposed and non-exposed neonates.
  • Lower birthweight was found in ENDS-exposed neonates compared to non-exposed neonates.
  • No significant difference in gestational age between ENDS-exposed and non-exposed neonates.

Why it matters

Understanding the risks associated with ENDS use during pregnancy is crucial for guiding clinical recommendations and interventions aimed at improving birth outcomes. This research highlights the potential risks of ENDS compared to non-nicotine exposure.

Source

PubMed · PMID 42176222

Published in Nicotine Tob Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.